These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25138390)

  • 1. The role of pharmacies and pharmacists in managing controlled substance dispensing.
    Hoppe J; Howland MA; Nelson L
    Pain Med; 2014 Dec; 15(12):1996-8. PubMed ID: 25138390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions.
    Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S
    J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An opioid dispensing and misuse prevention algorithm for community pharmacy practice.
    Rickles NM; Huang AL; Gunther MB; Chan WJ
    Res Social Adm Pharm; 2019 Aug; 15(8):959-965. PubMed ID: 29525483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacists' role in addressing opioid abuse, addiction, and diversion.
    J Am Pharm Assoc (2003); 2014; 54(1):e5-15. PubMed ID: 24257743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving use of narcotics for nonmalignant chronic pain: a lesson from Community Care of North Carolina.
    Bujold E; Huff J; Staton EW; Pace WD
    J Opioid Manag; 2012; 8(6):363-7. PubMed ID: 23264314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population health management in a small health system: Impact of controlled substance stewardship in a patient-centered medical home.
    Homsted FAE; Magee CE; Nesin N
    Am J Health Syst Pharm; 2017 Sep; 74(18):1468-1475. PubMed ID: 28887348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of Pharmacists in Addressing Medication Abuse in the Pacific Northwest.
    Nguyen DQ; Chung B; Osburn LL; Della Paolera MA; Chavez B
    J Pharm Pract; 2017 Oct; 30(5):528-533. PubMed ID: 27283869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges faced with opioid prescriptions in the community setting - Australian pharmacists' perspectives.
    Makdessi CJ; Day C; Chaar BB
    Res Social Adm Pharm; 2019 Aug; 15(8):966-973. PubMed ID: 30819418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.
    Winstock AR; Lea T; Sheridan J
    Addiction; 2010 Feb; 105(2):335-42. PubMed ID: 20078490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids.
    Woolf CJ; Hashmi M
    Curr Opin Investig Drugs; 2004 Jan; 5(1):61-6. PubMed ID: 14983975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescriber-pharmacist collaboration: re-engineering the partnership to optimize pain patient care.
    Ruble JH
    J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):365-6. PubMed ID: 24143929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and evaluation of a multidisciplinary controlled substances committee within a patient-centered medical home.
    Gernant SA; Bastien R; Lai A
    J Am Pharm Assoc (2003); 2015; 55(6):656-663. PubMed ID: 26547599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National drug control policy and prescription drug abuse: facts and fallacies.
    Manchikanti L
    Pain Physician; 2007 May; 10(3):399-424. PubMed ID: 17525776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-risk use by patients prescribed opioids for pain and its role in overdose deaths.
    Gwira Baumblatt JA; Wiedeman C; Dunn JR; Schaffner W; Paulozzi LJ; Jones TF
    JAMA Intern Med; 2014 May; 174(5):796-801. PubMed ID: 24589873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis.
    Hagemeier NE; Tudiver F; Brewster S; Hagy EJ; Ratliff B; Hagaman A; Pack RP
    Subst Abus; 2018 Jan; 39(1):89-94. PubMed ID: 28799863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacist-physician collaboration in pain management practice.
    Strickland JM; Huskey A; Brushwood DB
    J Opioid Manag; 2007; 3(6):295-301. PubMed ID: 18290580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid prescription underfilling among retail pharmacies.
    Reisfield G; Paulian G; Merlo L; Bertholf R; Wilson G
    Pain Med; 2010 Apr; 11(4):586-90. PubMed ID: 20113412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain reliever abuse communication.
    Hagemeier NE; Murawski MM; Lopez NC; Alamian A; Pack RP
    Res Social Adm Pharm; 2014; 10(3):562-75. PubMed ID: 23981913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective review of physician opioid prescribing practices in patients with aberrant behaviors.
    Gupta A; Patton C; Diskina D; Cheatle M
    Pain Physician; 2011; 14(4):383-9. PubMed ID: 21785482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
    Matthews ML
    J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.